These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 18398952

  • 1. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
    Soejima M, Kawaguchi Y, Hara M, Kamatani N.
    J Rheumatol; 2008 Apr; 35(4):724. PubMed ID: 18398952
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
    Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamanaka H, Saito T, Kamatani N.
    J Rheumatol; 2002 Dec; 29(12):2492-9. PubMed ID: 12465141
    [Abstract] [Full Text] [Related]

  • 4. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
    Taniguchi A, Kamatani N.
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
    Wiese MD, Alotaibi N, O'Doherty C, Sorich MJ, Suppiah V, Cleland LG, Proudman SM.
    Pharmacogenomics J; 2014 Aug; 14(4):350-5. PubMed ID: 24394199
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
    Taniguchi A, Urano W, Tanaka E, Akama H, Yamanaka H, Kamatani N.
    Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Is the cure worse than the disease?
    Sacks R.
    Aust Fam Physician; 2001 Jul; 30(7):679-80. PubMed ID: 11558203
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P.
    Methods Mol Biol; 2008 Jul; 448():413-35. PubMed ID: 18370240
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
    Jiang L, Zhao N, Ni L.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.